Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Eric's £50k share subscription declared along with another 1.8% for Jonathan Swan who declared his 3% back in March. The smart Money is accumulating. Gla :-)
It's going to big...On and UP!!! Gla :-)
Cheers Porter, an excellent and informative interview and very encouraging on prospects and potential going forward. Exciting times ahead. Gl :-)
Great find Northeast and exciting news for Genflow. Gl :-)
First in human proof-of-concept Phase I/ II Trial in NASH
NASH or Non-Alcoholic Steatohepatitis is a liver disease with a significant unmet medical need. Effecting an estimated 35 million people worldwide, it is the most chronic liver condition in the West and patient numbers are growing rapidly. It is the leading cause of liver transplants due to the lack of approved therapies with the market for NASH therapy expected to reach $27.2B by 2029.
Recent pre-clinical programs have highlighted the adipogenic, anti-fibrotic, and anti-tumoral effects of GF-1002 positioning it as a promising treatment candidate for NASH.
By targeting NASH, Genflow Biosciences stands to benefit from a clear regulatory pathway that could lead to accelerated development and the potential for conditional fast-track approval.
It's all good and now look forward to a flow if positive news. Gla ;-)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,558 followers
7h
The first #NASH treatment is FDA approved! Despite its growing rates, the disease went largely understudied for decades - until now. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) and its peers are developing life saving medicine to change the lives of millions.
Read more: htTps://loom.ly/fYAsZzA
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
PUBLISHED TUE, MAR 19 2024
In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals' drug "Rezdiffra," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.
The agency's approval is also a big deal because it means Madrigal has succeeded in an area where several other drugmakers have failed – or are still trying to crack.
That gives Madrigal an edge in a market that could be huge: The MASH industry could be worth nearly $26 billion by 2032 across the U.S., France, Germany, Italy, Spain, the U.K. and Japan, according to an estimate from data analytics firm GlobalData.
Madrigal's drug is setting the bar for efficacy and safety for MASH treatment, while also opening the door for medicines still in development.
There's one important detail in the approval that could bode well for the entire MASH space: The FDA isn't requiring patients to get a liver biopsy to determine their eligibility for Madrigal's drug.
That refers to a procedure in which a doctor removes a small piece of liver tissue from a patient so they can examine it under a microscope for signs of damage or disease.
"The absence of liver biopsy requirement in Rezdiffra's label should buoy biotech stocks" of companies developing MASH treatments and "potentially accelerate and broaden patient access," William Blair analyst Andy Hsieh wrote in a note on Friday.
htTps://www.cnbc.com/2024/03/19/healthy-returns-first-nash-liver-disease-drug-is-here-more-coming.html
March 2024 Company Presentation
hTtps://genflowbio.com/wp-content/uploads/2024/03/GenflowBio_Presentation_3-6-24.pdf
That's my plan......On and UP!!! Gla ;-)
Lol, you've got a few more than me Northeast, but i'll be closing the gap tomorrow if all goes to plan. The current rockbottom low sp could be the bargain of the century in the not too distant , with multiple potential opportunities /scenarios to propel Genflow’s value skywards. Gl :-)
Plenty of buying today Northeast, but hopefully no news just yet as I'm planning to buy a few myself tomorrow, with funds incoming. Gl :-)
Yes indeed Northeast, no doubt Madrigal will want to protect/dominate the Nash space by acquisition , as well as other Major's currently involved in Nash R & D...... Exciting times ahead. Gl ;-)
Other biopharma players including Pfizer, Bristol Myers Squibb and Genfit have all tried to get into the NASH field as well. Madrigal’s offering, meanwhile, was the first to meet the goals of both MASH resolution and fibrosis improvement in a phase 3 study.
The company is pricing Rezdiffra at a wholesale acquisition cost of $47,400 before discounts. Analysts at Evercore ISI have previously pegged peak global sales at $5.5 billion, and the analyst team expects the drug to generate about $2.6 billion in 2030.
Crucially, the FDA’s approval comes without the requirement of a liver biopsy to determine patient eligibility. That was a major point of contention among investors ahead of the approval, as the invasive procedure would have constrained wide access to the med.
hTtps://www.fiercepharma.com/pharma/after-monumental-mash-nod-its-rezdiffra-madrigal-plots-600m-stock-sale-support-upcoming
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,546 followers
3d
Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is glad to see the mounting interest in Nonalcoholic Steatohepatitis (NASH). The field was notably understudied until recently, when Genflow Biosciences and fellow pioneers began developing promising new treatments revolving around #SIRT6.
Our CEO, Dr Eric Leire, points to a recent EMBO Press report as an example of the growing attention, which also lends support to our research in #NASH.
Read the report here: hTtps://loom.ly/Z_O_-tE
FDA approves Madrigal’s Rezdiffra as first drug for fatty liver disease NASH
Over six million people in the US are affected by NASH with moderate-to-advanced liver scarring
19th March 2024
The US Food and Drug Administration (FDA) has approved Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis, alongside diet and exercise.
Based on results from the MAESTRO-NASH trial, the accelerated approval marks Rezdiffra as the first treatment option available to address notable liver scarring and liver damage.
htTps://pmlive.com/pharma_news/fda-approves-madrigals-rezdiffra-as-first-drug-for-fatty-liver-disease-nash/
HTtps://uk.marketscreener.com/insider/JONATHAN-SWANN-A256MW/
TR1 - Major Holdings Notification
Name
Jonathan Mark Swann
City of registered office (if applicable)
rickmansworth
Country of registered office (if applicable)
United Kingdom
RNS Number : 6661H
Genflow Biosciences PLC
21 March 2024
21 March 2024
Genflow Biosciences Plc
Announces Publication of a Key European Patent in Partnership with University of Rochester, New York, et al.
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce a significant milestone in its journey. Genflow's collaborative partners, including the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, have received confirmation that their European patent application was published today by the European Patent Office, bearing the reference number EP 4 338 267.
Innovation in Age-Related Disease Prevention and Treatment
The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," enhances the understanding and potential treatment of diseases associated with aging by focusing on the SIRT6 gene/protein, known for its critical role in DNA repair, metabolism, and longevity.
SIRT6 regulates DNA damage repair, specifically double strand breaks (DSB) and prevents or delays aging of cells. Genflow's lead drug candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene. Genflow is currently undertaking key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of GF-1002 and its potential benefits, initially, for non-alcoholic steatohepatitis (NASH) patients.
In 2023, the Company received positive feedback from the Federal Agency for Medicines and Health Products in Belgium and expects a follow-up meeting in Q2 2024 to finalise design of Phase/II clinical trials. NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD) characterized by excessive fat deposits in the liver, is usually a silent disease with few, if any, symptoms, and effective treatments.
Dr. Eric Leire, CEO of Genflow commented: "This approval from the European Patent Office highlights the innovative spirit of our collaborative team and we are incredibly proud to be part of this pioneering research alongside such respected institutions." He continued, "This patent represents a leap forward in our understanding and capabilities in treating age-related conditions and marks a significant step forward in our mission to develop effective therapies for NASH and other age-related diseases."
Yep, he also hinted at institutional investors which would make all the difference to current sp performance. Gl ;-)
Eric's presentation. Gla ;-)
Genflow Biosciences Plc (OTCQB: GENFF | LSE: GENF): Virtual Investor Conferences
hTtps://www.youtube.com/watch?v=0ZhaxbymGk4